Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model

Wang, Xinhui; Gong, Guoqing; Yang, Wei; Li, Yunzhan; Jiang, Meiling; Li, Linlin

doi:10.1016/j.etap.2013.04.004

Cited by 70 publications

(48 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1) is a naturally active flavonoid extracted from the propolis and root of Alpinia officinarum Hance; a plant that has been used as spice and a herbal medicine for various ailments in Asia for centuries [5]. The biological activities of galangin include antimutagenic, anticlastogenic, antioxidative, radical scavenging, metabolic enzyme modulating, bactericidal and antifibrotic [5][6][7]. Galangin also exhibits anti-inflammatory properties in collagen-induced arthritis and ovalbumin-induced airway inflammation via negative regulation of the nuclear factor-jB signaling [8,9].…”

Section: Introductionmentioning

confidence: 99%

Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo

Zhu

Luo

et al. 2014

Chemico-Biological Interactions

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo

Zhu

Luo

et al. 2014

Chemico-Biological Interactions

View full text Add to dashboard Cite

“…Galangin is a natural flavonol, which is extracted from Alpinia officinarum (6). It has been reported that galangin exerts anti-inflammatory effects on mast cell-derived allergies and collagen-induced arthritis via the suppression of receptor activator of nuclear factor (NF)-κB ligand-induced activation of Janus kinase, p38 and NF-κB pathways (7).…”

Section: Introductionmentioning

confidence: 99%

Galangin decreases p‑tau, Aβ42 and β‑secretase levels, and suppresses autophagy in okadaic acid‑induced PC12 cells via an Akt/GSK3β/mTOR signaling‑dependent mechanism

Huang

Zhong

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

Okadaic acid (OA)-induced neurotoxicity may be considered a novel tool used to study Alzheimer's disease (AD) pathology, and may be helpful in the development of a novel therapeutic approach. It has been reported that galangin inhibits β-site amyloid precursor protein-cleaving enzyme 1 expression, which is a key enzyme for amyloid β (Aβ) generation and is a potential drug candidate for AD therapy. However, further studies are required to confirm its neuroprotective effects in other AD models. The present study aimed to explore the neuroprotective effects of galangin on OA-induced neurotoxicity in PC12 cells. The cells were divided into the following groups: Control group, model group (175 nM OA for 48 h) and galangin groups (0.25, 0.5 and 1 µg/ml). Beclin-1, phosphorylated (p)-protein kinase B (Akt), p-glycogen synthase kinase (GSK)3β and p-mechanistic target of rapamycin (mTOR) expression was also measured in the following PC12 cell groups: Control group, model group, 3-methyladenine group (5 nM), rapamycin group (100 nM) and galangin group (1 µg/ml). The levels of β-secretase, Aβ 42 and p-tau were detected by ELISA, Beclin-1 expression was examined by immunohistochemistry and the protein expression levels of p-Akt, p-mTOR p-GSK3β, and Beclin-1 were detected by western blotting. Galangin treatment enhanced cell viability in cells treated with OA, and decreased β-secretase, Aβ 42 and p-tau levels. In addition, it suppressed Beclin-1 and p-GSK3β expression, but promoted p-Akt and p-mTOR expression by regulating the Akt/GSK3β/mTOR pathway. These results indicated that galangin protected PC12 cells from OA-induced cytotoxicity and inhibited autophagy via the Akt/GSK3β/mTOR pathway, thus suggesting that it may be considered a potential therapeutic agent for AD.

show abstract

“…T-kininogen 1 is a new potential 323 serum biomarker for inflammatory hepatic lesions [47] . Extracellular superoxide dismutase 324 activities in liver homogenates is significantly decreased in the CCl4-treated liver fibrosis 325 rat model [48] . Neutrophil gelatinase-associated lipocalin is a urine biomarker of acute-on-…”

mentioning

confidence: 99%

“…43 Liver fibrosis and cirrhosis are commonly studied using rat models [8] . Among the 44 liver fibrosis animal models, which are induced by bile duct ligation (BDL) [9] , ethanol 45 [10] , carbon tetrachloride (CCl4) [11] or thioacetamide (TAA) [12] , the intraperitoneally 46 TAA-injected rat model is widely used to induce liver fibrosis and cirrhosis and 47 consistently produces liver fibrosis and cirrhosis in rats with a histopathology that is more 48 similar to that of human liver fibrosis and cirrhosis [13][14][15] . In 1948, TAA was first reported 49 as a hepatotoxic agent [16] .…”

mentioning

confidence: 99%

Early urinary candidate biomarker discovery in a rat thioacetamide-induced liver fibrosis model

Zhang

Yuan

et al. 2017

Preprint

View full text Add to dashboard Cite

Biomarker is the change associated with the disease. Blood is relatively stable because of the homeostatic mechanisms of the body. However, urine accumulates changes of the body, which makes it a better early biomarker source. Liver fibrosis, which results from the deposition of extracellular matrix (ECM) components, is a reversible pathological condition, whereas cirrhosis, the end-stage of liver fibrosis, is irreversible. Consequently, noninvasive early biomarkers for fibrosis are desperately needed. In this study, differential urinary proteins were identified in the thioacetamide (TAA) liver fibrosis rat model using tandem mass tagging and two-dimensional liquid chromatography tandem mass spectrometry (2DLC-MS/MS). A total of 766 urinary proteins were identified, 143 and 118 of which were significantly changed in the TAA 1-week and 3-week groups, respectively. Multiple reaction monitoring (MRM)-targeted proteomics was used to further validate the abundant differentially expressed proteins in the TAA 1-week, 3-week, 6-week and 8-week groups. A total of 40 urinary proteins were statistically significant (fold change >2 and p<0.05), 15 of which had been previously reported as biomarkers of liver fibrosis, cirrhosis or other related diseases and 10 of which had been reported to be associated with the pathology and mechanism of liver fibrosis. These differential proteins were detected in urine before the alanine aminotransferase (ALT) and aspartate transaminase (AST) changes in the serum and before fibrosis was observed upon hematoxylin and eosin (HE) and Masson’s staining.

show abstract

Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model

Cited by 70 publications

References 21 publications

Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo

Galangin inhibits growth of human head and neck squamous carcinoma cells in vitro and in vivo

Galangin decreases p‑tau, Aβ42 and β‑secretase levels, and suppresses autophagy in okadaic acid‑induced PC12 cells via an Akt/GSK3β/mTOR signaling‑dependent mechanism

Early urinary candidate biomarker discovery in a rat thioacetamide-induced liver fibrosis model

Contact Info

Product

Resources

About